title: Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
abstract: Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with myelodysplastic syndrome (MDS). Because MDS predominantly affects an older population, age-associated comorbidities can preclude patients from cure. HSCT is associated with the risk of morbidity and mortality; however, with safer conditioning regimens and improved supportive care, eligible patients with an appropriately matched donor can receive this therapy without exclusion by older age alone. We discuss the role of improved MDS prognostic scoring systems and molecular testing for selection for HSCT, and review the pre-HSCT tolerability assessment required for this advanced aged population.
authors: Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL. Electronic address: asmita.mishra@moffitt.org.
authors: Asmita
authors: A
authors: Mishra
authors: Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL.
authors: Claudio
authors: C
authors: Anasetti
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D019175:DNA Methylation / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D018579:Patient Selection; D011379:Prognosis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: HSCT; MDS; Myelodysplasia; Somatic mutations; Transplant Tolerability